Self-assembled dextrin nanogel as protein carrier: Controlled release and biological activity of IL-10

Biotechnology and Bioengineering

Volumn 108, Issue 8, 2011, Pages 1977-1986

  Carvalho, Vera ^a   Castanheira, Pedro ^b   Madureira, Pedro ^c,d   Ferreira, Sílvia A ^a   Costa, Carla ^e   Teixeira, João P ^e   Faro, Carlos ^b,f   Vilanova, Manuel ^c,d   Gama, Miguel ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b Bioinformatics Unit   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e NATIONAL INSTITUTE OF HEALTH   (Portugal)

^f UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anti inflammatory agent; Biocompatibility; Dextrin nanogel; Interleukin 10; Protein delivery system

Indexed keywords

ACTIVE PROTEINS; ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY AGENTS; C57BL/6 MICE; CONTROLLED RELEASE; CYTOKINES; DELIVERY SYSTEMS; GENOTOXICITIES; HOMODIMERS; IN-VIVO; INTERLEUKIN-10; LACTATE DEHYDROGENASE; MEDICAL CONDITIONS; NANOGELS; PROTEIN CARRIER; PROTEIN DELIVERY SYSTEM; PROTEIN DELIVERY SYSTEMS; PROTEIN STABILIZATION; RELEASE PROFILES; SELF-ASSEMBLED;

BIOACTIVITY; BIOCOMPATIBILITY; CYTOTOXICITY; MAMMALS; NANOSTRUCTURED MATERIALS; STABILIZATION;

PROTEINS;

DEXTRIN; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; NANOPARTICLE; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; BIOLOGICAL ACTIVITY; CELL MEDIATED CYTOTOXICITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GEL; GENOTOXICITY; MOUSE; NONHUMAN;

ANIMALS; DEXTRINS; DRUG CARRIERS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; PROTEIN DENATURATION; SERUM;

MUS;

EID: 79959189728     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23125     Document Type: Article

References (57)

1. Anderson D, Plewa MJ. 1998. The International Comet Assay Workshop. Mutagenesis 13(1): 67-73.
2. Anderson D, Yu TW, McGregor DB. 1998. Comet assay responses as indicators of carcinogen exposure. Mutagenesis 13(6): 539-555.
3. Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 55(2): 241-269.
4. Barnes CA, Elsaesser A, Arkusz J, Smok A, Palus J, Lesniak A, Salvati A, Hanrahan JP, de Jong WH, Dziubaltowska E, Stepnik M, Rydzynski K, McKerr G, Lynch I, Dawson KA, Howard CV. 2008. Reproducible Comet assay of amorphous silica nanoparticles detects no genotoxicity. Nano Lett 8(9): 3069-3074.
5. Berzofsky JA, Ahlers JD, Belyakov IM. 2001. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1(3): 209-219.
6. Bogdan C, Vodovotz Y, Nathan C. 1991. Macrophage deactivation by interleukin 10. J Exp Med 174(6): 1549-1555.
7. Branco MC, Schneider JP. 2009. Self-assembling materials for therapeutic delivery. Acta Biomater 5(3): 817-831.
8. Brendler-Schwaab S, Hartmann A, Pfuhler S, Speit G. 2005. The in vivo comet assay: Use and status in genotoxicity testing. Mutagenesis 20(4): 245-254.
9. Carvalho V, Castanheira P, Faria TQ, Goncalves C, Madureira P, Faro C, Domingues L, Brito RMM, Vilanova M, Gama FM. 2010. Biological activity of heterologous murine interleukin-10 and preliminary studies on the use of a dextrin nanogel as a delivery system. Int J Pharm 400: 234-242.
10. Chiellini EE, Chiellini F, Solaro R. 2006. Bioerodible polymeric nanoparticles for targeted delivery of proteic drugs. J Nanosci Nanotechnol 6(9-10): 3040-3047.
11. Collins AR, Dobson VL, Dusinska M, Kennedy G, Stetina R. 1997. The comet assay: What can it really tell us? Mutat Res Fundam Mol Mech Mutagen 375(2): 183-193.
12. Collins AR, Oscoz AA, Brunborg G, Gaivao I, Giovannelli L, Kruszewski M, Smith CC, Stetina R. 2008. The comet assay: Topical issues. Mutagenesis 23(3): 143-151.
13. Costa S, Coelho P, Costa C, Silva S, Mayan O, Santos LS, Gaspar J, Teixeira JP. 2008. Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde. Toxicology 252(1-3): 40-48.
14. Creery WD, Diaz-Mitoma F, Filion L, Kumar A. 1996. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol 26(6): 1273-1277.
15. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. 1991a. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174(5): 1209-1220.
16. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE. 1991b. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174(4): 915-924.
17. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. 1992. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 175(3): 671-682.
18. Devalapally H, Chakilam A, Amiji MM. 2007. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 96(10): 2547-2565.
19. Fairbairn DW, Olive PL, Oneill KL. 1995. The Comet Assay-a comprehensive review. Mutat Res Rev Genet Toxicol 339(1): 37-59.
20. Fichthorn KA, Qin Y. 2006. Molecular-dynamics simulation of colloidal nanoparticle forces. Ind Eng Chem Res 45(16): 5477-5481.
21. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. 1991. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147(11): 3815-3822.
22. Gazzinelli RT, Oswald IP, James SL, Sher A. 1992. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol 148(6): 1792-1796.
23. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177(2): 547-550.
24. Goncalves C, Gama FM. 2008. Characterization of the self-assembly process of hydrophobically modified dextrin. Eur Polym J 44(11): 3529-3534.
25. Goncalves C, Martins JA, Gama FM. 2007. Self-assembled nanoparticles of dextrin substituted with hexadecanethiol. Biomacromolecules 8(2): 392-398.
26. Goncalves C, Torrado E, Martins T, Pereira P, Pedrosa J, Gama M. 2010. Dextrin nanoparticles: Studies on the interaction with murine macrophages and blood clearance. Colloids Surf B-Biointerfaces 75(2): 483-489.
27. Groux H, Bigler M, de Vries JE, Roncarolo MG. 1998. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 160(7): 3188-3193.
28. Haag R, Kratz F. 2006. Polymer therapeutics: Concepts and applications. Angew Chem Int Ed Engl 45(8): 1198-1215.
29. Hasegawa U, Sawada S, Shimizu T, Kishida T, Otsuji E, Mazda O, Akiyoshi K. 2009. Raspberry-like assembly of cross-linked nanogels for protein delivery. J Control Release 140(3): 312-317.
30. Howard M, Muchamuel T, Andrade S, Menon S. 1993. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177(4): 1205-1208.
31. Hreczuk-Hirst D, Chicco D, German L, Duncan R. 2001. Dextrins as potential carriers for drug targeting: Tailored rates of dextrin degradation by introduction of pendant groups. Int J Pharm 230(1-2): 57-66.
32. Hubel K, Dale DC, Liles WC. 2002. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: Current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 185(10): 1490-1501.
33. Kim S, Kim JH, Jeon O, Kwon IC, Park K. 2009. Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm 71(3): 420-430.
34. Lee KY, Mooney DJ. 2001. Hydrogels for tissue engineering. Chem Rev 101(7): 1869-1879.
35. Lee KY, Yuk SH. 2007. Polymeric protein delivery systems. Prog Polym Sci 32(7): 669-697.
36. Leon LR, Kozak W, Rudolph K, Kluger MJ. 1999. An antipyretic role for interleukin-10 in LPS fever in mice. Am J Physiol 276(1 Pt 2): R81-R89.
37. Leonard M, De Boisseson MR, Hubert P, Dalencon F, Dellacherie E. 2004. Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J Control Release 98(3): 395-405.
38. Lukyanov AN, Torchilin VP. 2004. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56(9): 1273-1289.
39. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. 1990. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 145(12): 4167-4173.
40. Miyamae Y, Iwasaki K, Kinae N, Tsuda S, Murakami M, Tanaka M, Sasaki YF. 1997. Detection of DNA lesions induced by chemical mutagens using the single-cell gel electrophoresis (Comet) assay. 2. Relationship between DNA migration and alkaline condition. Mutat Res Genet Toxicol Environ Mutagen 393(1-2): 107-113.
41. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
42. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63.
43. Murthy N, Thng YX, Schuck S, Xu MC, Frechet JM. 2002. A novel strategy for encapsulation and release of proteins: Hydrogels and microgels with acid-labile acetal cross-linkers. J Am Chem Soc 124(42): 12398-12399.
44. Murthy N, Xu M, Schuck S, Kunisawa J, Shastri N, Frechet JM. 2003. A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels. Proc Natl Acad Sci USA 100(9): 4995-5000.
45. Nair LS, Laurencin CT. 2006. Polymers as biomaterials for tissue engineering and controlled drug delivery. Tissue Eng I: Scaffold Syst Tissue Eng 102: 47-90.
46. Nayak S, Lyon LA. 2005. Soft nanotechnology with soft nanoparticles. Angew Chem Int Ed Engl 44(47): 7686-7708.
47. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. 2004. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929-979.
48. Pullerits T. 2002. Cytokine modulation for anti-allergic treatment. Curr Pharm Des 8(20): 1845-1853.
49. Shimizu T, Kishida T, Hasegawa U, Ueda Y, Imanishi J, Yamagishi H, Akiyoshi K, Otsuji E, Mazda O. 2008. Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. Biochem Biophys Res Commun 367(2): 330-335.
50. Singh NP, Mccoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low-levels of DNA damage in individual cells. Exp Cell Res 175(1): 184-191.
51. Tan ML, Choong PF, Dass CR. 2010. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 31(1): 184-193.
52. Tang Y, Li B, Wang N, Xie Y, Wang L, Yuan Q, Zhang F, Qin J, Peng Z, Ning W, Wang L, Hu G, Li J, Tao L. 2010. Fluorofenidone protects mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-1beta release. Int Immunopharmacol 10(5): 580-583.
53. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35(3): 206-221.
54. Tushinski RJ, Oliver IT, Guilbert LJ, Tynan PW, Warner JR, Stanley ER. 1982. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 28(1): 71-81.
55. Wan JM, Sit WH, Lee CL, Fu KH, Chan DK. 2006. Protection of lethal toxicity of endotoxin by salvia miltiorrhiza BUNGE is via reduction in tumor necrosis factor alpha release and liver injury. Int Immunopharmacol 6(5): 750-758.
56. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, de Boer M, Goldman M. 1994. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24(4): 1007-1009.
57. Zhang X, Goncalves R, Mosser DM. 2008. The isolation and characterization of murine macrophages. Curr Protoc Immunol 83: 14.1.1-14.1.14.